Monovaccine (Epstein - Barr virus) Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-01-22　·　151 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 8.34 Bn
2033 年預估規模: USD 12.05 Bn
年複合成長率 CAGR: 5.4%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-01-22頁數 151報告編號 CMI2002

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Monovaccine (Epstein - Barr virus) Market, By Application (Mononucleosis, Endemic Burkitts Lymphoma, Hodgkins Lymphoma, Gastric Carcinomas, Multiple sclerosis, and Nasopharyngeal Carcinoma), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

報告摘要

Epstein-Barr virus (EBV) infects human B cells and spreads the infection throughout the entire reticuloendothelial system (RES). The virus is known to cause various autoimmune disorders including multiple sclerosis, celiac disease, systemic lupus erythematosus, juvenile idiopathic arthritis, inflammatory bowel disease, rheumatoid arthritis, and type 1 diabetes. Various research studies have linked Epstein-Barr virus to certain cancers of the lymphatic system and lupus. For instance, according to the report from the Cincinnati Children's Hospital Medical Center, in 2018, infection with the Epstein-Barr virus (EBV) increases the risk of developing multiple sclerosis. When the human body encounters foreign bodies such as virus or bacteria, it uses B-cells to produce antibodies to fight against these agents. However, in Epstein-Barr infections, the virus invades and takes control of B-cells. EBV invades B cells by producing abnormal transcription factors that regulate gene expression. The researchers revealed that virus-derived EBNA2 transcription factor binds to several spots in the human genome that are linked to above mentioned diseases. Moreover, EBV is linked with several human cancers such as Burkitt’s lymphoma, nasopharyngeal carcinoma, and post-transplant lymphoproliferative disorder. However, the exact reason for EBV leading to different types of cancers is currently being studied by various researchers. For instance, according to the study published in Gynecologic Oncology Journal, 2017, researchers from the Federal University of Cariri stated that cervical carcinoma was four times more prevalent among EBV positive women than in women without EBV infection. This indicated that EBV infection increases the risk of cervical carcinoma. Market Dynamics • Various universities are involved in frequent research and development activities for development of novel monovaccines. • For instance, since 2017, University of Kansas School of Engineering and School of Pharmacy is studying genetics of human immune responses to produce a potent vaccine for Epstein - Barr virus or EBV. Such increasing research activities by various organizations for development of novel vaccines for EBV is expected to drive the global monovaccines (Epstein - Barr virus) market growth. • Furthermore, high prevalence of various diseases related to EBV virus is expected to rise demand for its vaccine in future. • For instance, according to data published by Cancer Research U.K. in 2014, around 62,400 cases of Hodgkin’s lymphoma were recorded worldwide, out of which around 28,600 cases were associated with Epstein-Barr virus. According to the same source, it was estimated that EBV is responsible for an estimated 45% of Hodgkin’s lymphoma in the U.K., annually. • According to data published by Cancer Research U.K. in 2014, EBV is a very common virus that can increase the risk of nasopharyngeal cancer. According to same source, there were around 80,000 cases of nasopharyngeal carcinoma worldwide, out of which around 78,100 cases were associated with Epstein-Barr virus. Key features of the study • This report provides in-depth analysis of global monovaccine (Epstein-Barr Virus) market and provides market potential (US$ Billion) • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market • This study also provides key insights about market drivers, restraints, opportunities, regional outlook, and competitive strategy adopted by leading players • It profiles leading players in the global monovaccine (Epstein-Barr Virus) market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans • Universities and organizations involved in development of monovaccine (Epstein-Barr virus) includes Cancer Research U.K., National Institutes of Health, Chinese University of Hong Kong, Genocea Biosciences, Inc., Dana-Farber Cancer Institute, German Cancer Research Institute, and University of Minnesota • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics • The global monovaccine (Epstein-Barr Virus) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global monovaccine (Epstein-Barr Virus) market Market Segmentation • By Application o Mononucleosis o Endemic Burkitt’s Lymphoma o Hodgkin’s Lymphoma o Gastric Carcinomas o Multiple sclerosis o Nasopharyngeal Carcinoma • By Region o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East & Africa  GCC Countries  Israel  Rest of Middle East & Africa • Key Players o Cancer Research UK o National Institutes of Health o Chinese University of Hong Kong o Genocea Biosciences, Inc. o Dana-Farber Cancer Institute o German Cancer Research Institute o University of Minnesota

目錄 Table of Contents

Table of Contents 1. Research Objective and Assumption o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Market Snippet, By Application  Market Snippet, By Region  Coherent Opportunity Map (COM) 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics o Drivers o Restraints o Market Opportunities o Impact Analysis o Pipeline Analysis 4. Global Monovaccine (Epstein-Barr Virus) Market, By Application, 2026 -2033 (US$ Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-O-Y Growth Analysis, 2026 - 2033  Segment Trends o Mononucleosis  Introduction  Market Size and Forecast, and Y-O-Y Growth, 2026 - 2033, (US$ Bn) o Endemic Burkitt’s Lymphoma  Introduction  Market Size and Forecast, and Y-O-Y Growth, 2026 - 2033, (US$ Bn) o Hodgkin’s Lymphoma  Introduction  Market Size and Forecast, and Y-O-Y Growth, 2026 - 2033, (US$ Bn) o Gastric Carcinomas  Introduction  Market Size and Forecast, and Y-O-Y Growth, 2026 - 2033, (US$ Bn) o Multiple sclerosis  Introduction  Market Size and Forecast, and Y-O-Y Growth, 2026 - 2033, (US$ Bn) o Nasopharyngeal Carcinoma  Introduction  Market Size and Forecast, and Y-O-Y Growth, 2026 - 2033, (US$ Bn) 5. Global Monovaccine (Epstein-Barr Virus) Market, By Region o Introduction  Market Share Analysis, By Region, 2026 and 2033 (%)  Y-O-Y Growth Analysis, For Region, 2026 - 2033 o North America  Market Share Analysis, By Country, 2026 and 2033 (%)  Y-O-Y Growth Analysis, By Country, 2026 - 2033 o U.S.  Country Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) o Canada  Country Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) o Latin America  Market Share Analysis, By Country, 2026 and 2033 (%)  Y-O-Y Growth Analysis, By Country, 2026 - 2033 o Brazil  Country Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) o Argentina  Country Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) o Mexico  Country Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) o Rest of Latin America  Country/Region Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) o Europe  Market Share Analysis, By Country, 2026 and 2033 (%)  Y-O-Y Growth Analysis, By Country, 2026 - 2033 o U.K.  Country Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) o Germany  Country Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) o Italy  Country Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) o Spain  Country Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) o France  Country Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) o Russia  Country Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) o Rest of Europe  Country Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) o Asia Pacific  Market Share Analysis, By Country, 2026 and 2033 (%)  Y-O-Y Growth Analysis, By Country, 2026 - 2033 o China  Country Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) o India  Country Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) o Japan  Country Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) o ASEAN  Country Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) o South Korea  Country Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) o Australia  Country Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) o Rest of Asia Pacific  Country/Region Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) o Middle East  Market Share Analysis, By Country/Region, 2026 and 2033 (%)  Y-O-Y Growth Analysis, By Country/Region, 2026 - 2033 o GCC  Country/Region Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) o Israel  Country/Region Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) o Rest of Middle East  Country/Region Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) o Africa  Market Share Analysis, By Country/Region, 2026 and 2033 (%)  Y-O-Y Growth Analysis, By Country/Region, 2026 - 2033 o Northern Africa  Country/Region Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) o Central Africa  Country/Region Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) o South Africa  Country/Region Trends  Market Size and Forecast, By Application, 2026 - 2033 (US$ Bn) 6. Competitive Landscape o Heat Map Analysis o Company Profiles  Cancer Research UK o Company Overview o Product Portfolio o Key Developments o Strategies  National Institutes of Health o Company Overview o Product Portfolio o Key Developments o Strategies  Chinese University of Hong Kong o Company Overview o Product Portfolio o Key Developments o Strategies  Genocea Biosciences, Inc. o Company Overview o Product Portfolio o Key Developments o Strategies  Dana-Farber Cancer Institute o Company Overview o Product Portfolio o Key Developments o Strategies  German Cancer Research Institute o Company Overview o Product Portfolio o Key Developments o Strategies  University of Minnesota o Company Overview o Product Portfolio o Key Developments o Strategies 7. Section o References o Research Methodology o About us and Sales Contact

提及公司

Cancer Research UKNational Institutes of HealthChinese University of Hong KongGenocea Biosciences, Inc.Dana-Farber Cancer InstituteGerman Cancer Research InstituteUniversity of Minnesota

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們